CAREERS CONTACT NEWS ABOUT PRODUCT PIPELINE INVESTORS INVESTOR OVERVIEW NEWS & EVENTS CORPORATE GOVERNANCE FINANCIALS & FILINGS CONTACT INVESTOR RELATIONS PARTNERS MEDICAL AFFAIRS Advancing a novel product pipeline of neurology therapies VIEW PRODUCT PIPELINE ABOUT We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy. READ MORE NEWS ALL NEWS PRODUCT PIPELINE Preclinical Phase 1 Phase 2 Phase 3 Approved XEN1101 for Adult Focal Epilepsy X-TOLE Clinical Trial XEN1101 for Major Depressive Disorder (MDD) Investigator-led Phase 2 POC study Collaboration with Mount Sinai XEN1101 for MDD Company-sponsored Phase 2 POC study XEN496 for Orphan Pediatric Epilepsy (KCNQ2-DEE) EPIK Clinical Trial NBI-921352 for Rare Pediatric Epilepsy: SCN8A-DEE Partnered with Neurocrine Biosciences NBI-921352 for Focal-Onset Seizures in Adults Partnered with Neurocrine Biosciences FX301 for Post-Operative Pain Partnered with Flexion Therapeutics INVESTORS Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events VIEW INVESTOR AREA OUR MANAGEMENT Learn more about Xenon's management group VIEW MANAGEMENT CAREERS See current career opportunities VIEW CAREERS EXPLORE THE SITE About Product Pipeline Investors Partners Medical Affairs Careers Contact News CONTACT XENON Xenon Pharmaceuticals Inc. 3650 Gilmore Way Burnaby, BC V5G 4W8 Tel: 604.484.3300 Fax: 604.484.3450 info@xenon-pharma.com “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. Copyright © 2019 Xenon® All rights reserved. Legal Terms of Site Use Privacy Notice